Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Thu 13 Dec 2007, 15:29 IMU - Imuniti Holdings - Clinical Trials On The Imuniti Wellness Pack Set To
IMU
 IMU                                                                             
IMU - Imuniti Holdings - Clinical Trials On The Imuniti Wellness Pack Set To    
                             Begin Early In January 2008                        
IMUNITI HOLDINGS LIMITED                                                        
(Registration number 2004/002282/06)                                            
(JSE Code: IMU & ISIN: ZAE000089199)                                            
("Imuniti" or "the Company")                                                    
CLINICAL TRIALS ON THE IMUNITI WELLNESS PACK SET TO BEGIN EARLY IN JANUARY      
2008                                                                            
A clinical trial contract has been signed between the Medical Research Council  
and Edge to Edge Global Investments Ltd. The clinical trials on the Imuniti     
Wellness Pack will begin early in January 2008. It is anticipated that the      
first phase of the trials will be completed by March 2008, and that the second  
and final phase will be completed by September 2008.                            
Trial protocols were designed in accordance with World Health Organization      
guidelines and were approved by the peer review committee of the Medicines      
Control Council of SA. The pack is unique in that it contains natural immune    
modulators, traditional medicines such as Sutherlandia (this plant is           
aggressively pursued by the Pharmaceutical Industry) and high protein food as   
well as a water sterilization agent. This unique product compilation is the     
outcome of a culmination of extensive development by various technology houses  
over a period of five years.                                                    
Due to the extremely positive nature of the anecdotal evidence gathered over a  
four year period, Imuniti Holdings and Edge to Edge Global Investments Ltd are  
extremely confident that the trial will pass the Quality of Life parameters.    
This outcome could make the product unique in the world and due to the fact     
that the product is natural, any HIV and AIDS patient could then use the        
product. However should the trial succeed showing blood results, with respect   
to CD counts and viral loads then the product could fall into the category of   
a natural "Anti Retroviral", which has been scientifically proven. The outcome  
as portrayed could be Immeasurable. Furthermore the treatment regime of the     
product could be understood even by the most illiterate patients.               
It is with all this in mind that the recent MOU`s which have been signed        
between Edge to Edge Global investments Ltd, Imuniti Holdings and the Africa    
Forum becomes extremely significant as the forum has indicated that they could  
pave the way for access to all their respective countries and also potential    
donors. The Africa Forum currently consists of 37 democratic former African     
Heads Of State and other highly influential recognized individuals including    
the likes of Nelson Mandela, Alberto Chissano and Kenneth Kaunda. The Forum     
has realised the debilitating impact that HIV and AIDS is having on the         
African economy as a whole and have selected a solution in the form of the      
Imuniti Wellness Packs.                                                         
Pretoria                                                                        
13 December 2007                                                                
DESIGNATED ADVISER:                                                             
EXCHANGE SPONSORS (PTY) LIMITED                                                 
Date: 13/12/2007 15:29:49 Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
[  Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: